Stable Angina Medical Therapy
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prolonged nitrate-free intervals for nitrate levels to decline before the next dose. 6, 7, 9, 12 Long-acting nitrates have been downgraded to second-line therapy in guidelines because of their side-effects and the incidence of tachyphylaxis.
The first reported use of BBs to treat hypertension and angina was in the 1970s in the UK. 13, 14 BBs are an effective therapy in the management of stable angina. [14] [15] [16] [17] Many BB are available for clinical use. They have the common property of blocking beta-adrenergic receptors and selective and non-selective BB can be chosen for their different properties.
Although BB can reduce mortality and morbidity in patients with heart failure with reduced ejection fraction and in patients with recent MI, these agents have a limited effect on mortality and the incidence of MI when used in patients with stable angina. [18] [19] [20] [21] [22] [23] [24] [25] [26] CCBs, both dihydropyridine (DHP) agents and non-DHP agents, have been used for more than five decades, and are very effective for the treatment of stable angina. They significantly reduce the episodes of angina, increase exercise duration and decrease the frequency of nitroglycerin use. [27] [28] [29] [30] When combined with BB, they have been shown to significantly delay the onset of ST-segment depression using an exercise treadmill test. 31 Patients with asthma or chronic obstructive pulmonary disease (COPD) are good candidates for treatment with CCB, given the risk of bronchospasm in these patients when taking BB. 32 A combination of BB and non-DHP CCB should be avoided due to the risk of symptomatic bradycardia and atrioventricular block. 33 Nicorandil, Ranolazine, Trimetazidine, Ivabradine and Allopurinol
Nicorandil, which is a nitrate-moiety nicotinamide ester and adenosine-sensitive potassium channel opener, increases coronary blood flow and prevents coronary artery spasm. 34 It has been approved for clinical use in Japan and many European countries on the basis of small trials in patients with stable angina. 35, 36 This medication is not used in the US because placebo-controlled studies from Australia and the US failed to confirm antianginal efficacy of nicorandil compared with placebo. 37 In Europe, it has been used instead of nitrates or in combination with other antianginals. 37 Sideeffects of gastrointestinal ulcerations and headache limit the longterm use of nicorandil in patients with stable angina. 38, 39 Ranolazine is an orally active piperazine derivative. 40 The exact mechanism its antianginal action is unknown, but animal studies have shown that it inhibits late sodium inward current during periods of ischaemia, reducing intracellular calcium overload. 41, 42 Ranolazine is an effective antianginal and anti-ischaemic agent compared with placebo and is as equally effective as atenolol. 43, 44 Extended-release ranolazine compared with placebo, as monotherapy or in combination with other antianginals, has been shown to significantly increased total exercise time by 116 seconds and 23.7 seconds, respectively. 43, 44 It also increased treadmill walking time for people with angina and delayed the onset of exercise-induced MI. 43, 45, 46 Ranolazine has been shown to be ineffective in the treatment of women with microvascular angina compared with placebo. 47 Trimetazidine is available in Europe and several countries in Asia as an adjunct therapy for angina, but it is not used in the US. 4, 35, 48 In patients who remain symptomatic despite treatment with first-line therapy drugs, trimetazidine decreases angina frequency without exerting any effects on heart rate or blood pressure, as shown in the TRIMetazidine in POLand (TRIMPOL) trials I and II. 49, 50 Allopurinol is a pyrazolopyrimidine and an analogue of hypoxanthine. 51, 52 It has been demonstrated that high-dose allopurinol is associated with a significant improvement in endothelium-dependent vasodilation and exercise tolerance. The effects of high-dose allopurinol (600 mg daily) have been shown to be similar to conventional antianginal medications. 53 While recommended in the European Society of Cardiology (ESC) guidelines as a second-or third-line agent for symptom control, allopurinol is not endorsed in the National Institute 
for Health and Care Excellence (NICE) guidelines. 35, 54, 55 Allopurinol is not approved by the Food and Drug Administration to treat angina in the US.
Ivabradine lowers heart rate and inhibits the primary sinoatrial node current. 56 It is use-dependent, meaning that its effect is the highest in high heart rate and vice versa; bradycardia is less commonly encountered in patients on ivabradine because its effect is ameliorated at lower heart rates. 57 Studies have shown that ivabradine as an add-on therapy to atenolol significantly increased exercise time and reduces the number of angina attacks compared with atenolol alone or other BB and it did not cause significant bradycardia. [58] [59] [60] [61] However, symptomatic bradycardia remains a concern when using combination therapy, and it may adversely affect outcome in severely symptomatic patients. 33 In patients with stable angina without heart failure, ivabradine added to background therapy was shown not to decrease the incidence of death from cardiovascular causes or non-fatal MI, but in a subgroup of patients with severe angina, ivabradine performed worse than placebo with regards to hard endpoints. 62 
Combination Antianginal Therapy
Monotherapy in optimal doses,is often as effective as combination therapy using two or more agents. 3, 4, 35, 63, 64 There is a lack of welldesigned studies showing that treatment with more than one class of drug is superior to combination treatment with a different class of antianginal drugs. 65, 66 Adding either a long-acting nitrate or a CCB to BB therapy is often useful and reduces angina frequency, improves exercise tolerance and reduces MI. 63, 65 A combination of BB and ivabradine has been shown to be effective in patients with a heart rate greater than 60 BPM, but safety concerns have been raised. 62, 67 As discussed earlier, extended release ranolazine monotherapy, or in combination with BB or CCB, is effective. 43, 45, 46 Trimetazidine as an addon to older antianginal drugs has also been shown to be effective. 44, 45 None 
Guidelines for Stable Angina
There are published guidelines for the management of patients with stable ischaemic heart disease and stable angina. • Class I where the evidence and/or general agreement that a given treatment or procedure is beneficial, useful and effective.
• Class IIa where the weight of evidence or opinion is in favour of usefulness/efficacy.
• Class IIb where usefulness/efficacy is less well established by evidence or opinion.
• Class III where there is evidence or general agreement that the given treatment or procedure is not useful/effective and in some cases may be harmful. 35 In addition, for each class of recommendation, a level of evidence is included:
• Level of evidence A denotes that data were derived from multiple randomised clinical trials or meta-analyses.
• Level of evidence B indicates that data were derived from a single randomised clinical trial or large non-randomised studies.
• Level of evidence C is where a consensus of opinion of the experts and/or small studies, retrospective studies or registries were available. 35 NICE guidelines ( Table 1 ) are based on extensive reviews of published data and take into consideration cost-effectiveness and the adverse effects of medications. The terms first-line treatment and second-line treatment are used and guidance is given on the most appropriate use of antianginal therapy, taking co-morbidities into consideration when selecting therapy.
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Guidelines for Antianginal Therapy 
Co-morbidities and Stable Angina
Both guidelines recommend use of specific antianginal medications, taking into consideration the presence or absence of comorbidities such as COPD, hypertension, peripheral vascular disease and diabetes, despite the lack of randomised controlled trials to support this. 64, 65, 68 Guidelines to Reduce MI and Sudden Cardiac Death
Lifestyle Changes
Smoking cessation or abstinence reduces the risk of CAD mortality by 50% in 1 year and after 5-15 years the coronary mortality risk reaches that of non-smokers. 69 In addition to decreasing cardiovascular mortality and morbidity, stopping smoking in patients with angina also increases exercise performance. 64 Although based on small observational studies, exercise training was shown to have favourable outcomes in patients with stable angina. 70 Both guidelines emphasise the importance of smoking cessation and regular exercise. NICE guidelines do not specify any special diets, while ESC guidelines recommend a Mediterranean diet. Cardiac rehabilitation is recommended in ESC guidelines, but not in NICE guidelines.
Antiplatelet Therapy
Both guidelines recommend daily use of low-dose aspirin because it has been shown to reduce the incidence of acute MI and sudden death in patients with known CAD. 71 This has only been shown to be effective for patients with stable angina in a small study. 72 The use of aspirin in patients with stable angina in the absence of CAD is uncertain. 65 In patients who are allergic to aspirin, clopidogrel may be used instead according to ESC guidelines, but is not evidence-based;
although routine combination of aspirin and a P2Y12 inhibitor is not recommended due to an excessive risk of bleeding.
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Treatment of Dyslipidaemia
There are no specific trials of statins in patients with stable angina, however this class of drugs reduce all-cause mortality, acute coronary events, and the need for revascularisation in patients with CAD and in those at high risk of CAD. 74, 75 ESC guidelines recommend the use of statins to achieve the ideal low-density lipoprotein goal (<1.8 mmol/l), while NICE guidelines recommend the use of high-dose statins, such as 80 mg atorvastatin ( Table 1) .
Control of Hypertension
There are no specific trials of antihypertensive medications in patients with stable angina who also have hypertension. But given the documented beneficial effects of controlling blood pressure on hard outcomes, especially stroke and heart failure, both guidelines recommend optimal control of blood pressure in patients with stable angina to reduce the incidence of stroke and MI. The blood pressure goal is <140 mmHg for systolic, however recent data suggest that lowering systolic blood pressure to 120 mmHg may be a desirable option if tolerated by the patient. 
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Management of Diabetes
Conclusion
The current guidelines are largely based on expert opinion and consensus rather than high-quality randomised controlled trials. The two documents discussed in this article make different recommendations for first-line treatment, as well as add-on treatment with two or three antianginal drugs, without objective data.
Secondary prevention strategies vary; however, the use of low-dose aspirin and statin therapy seem to be justified based on the available data. The management of patients with microvascular disease or normal coronary arteries and angina remains uncertain especially in the absence of randomised controlled trials. The guideline recommendations rely mostly on assumptions and extrapolations and expert opinion based on the available data regarding patients with obstructive CAD.
